Participant‐reported pain relief of 50% or greater · acute gout
NSAIDs may leads to higher pain: ≥ 50% improvement in pain (spontaneous pain at 24 hours) compared with placebo (low certainty).
1 finding from 1 review
RR 2.75 [1.13, 6.72]
Studies not reported
Low
Pain: mean decrease per hour on a VAS scale (0 to 100, 0 no pain) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Swelling (mean) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Function: walking disability during first 6 hours · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Global assessment of treatment success · acute gout
NSAIDs showed no clear difference in patients' global assessment of treatment success at day 3 to 4 compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 0.92 [0.7, 1.22]
Studies not reported
Moderate
HRQOL ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout
NSAIDs showed no clear difference in inflammation: swelling compared with placebo (low certainty).
1 finding from 1 review
RR 1.08 [0.79, 1.49]
Studies not reported
Low
Withdrawals due to adverse events · acute gout
NSAIDs showed no clear difference in withdrawals due to adverse events compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 2.8 [0.55, 14.22]
Studies not reported
Moderate
Total adverse events · acute gout
NSAIDs probably leads to higher total adverse events compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 1.62 [1.03, 2.55]
Studies not reported
Moderate
Function: ≥ 50% improvement in pain with movement at 24 hours · acute gout
NSAIDs showed no clear difference in function: ≥ 50% improvement in pain with movement at 24 hours compared with placebo (low certainty).
1 finding from 1 review
RR 4 [0.5, 31.74]
Studies not reported
Low
Participants' global assessment of treatment: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Health‐related quality of life: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Total adverse events · acute gout
NSAIDs showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.2 [0.01, 3.85]
Studies not reported
Low
Functional disability at 3 months ‐ not measured · Adults with lateral elbow pain
1 finding from 1 review
Withdrawals due to adverse events · Adults with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Adults with lateral elbow pain
1 finding from 1 review
Pain 0 to 100 visual analogue scale and 10‐point Likert scale (lower score = less pain) · Adults with lateral elbow pain
1 finding from 1 review
Treatment success Fair, good or excellent effectiveness · Adults with lateral elbow pain
It is very uncertain whether oral NSAIDs changes treatment success Fair, good or excellent effectiveness compared with glucocorticoid injection (very low certainty).
1 finding from 1 review
Quality of life · Adults with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found